Skip to main content

Table 3 Distribution of resistance phenotypesa among inpatient and outpatient MRSAb

From: Laboratory-based surveillance of current antimicrobial resistance patterns and trends among Staphylococcus aureus: 2005 status in the United States

   Inpatient Outpatient
Category Resistance phenotype n (%) n (%)
Susceptible to all other agents - 418 (4.1) 245 (5.7)
Single-drug resistant Eryth 1409 (13.7) 1200 (27.8)
  Cipro 232 (2.2) 92 (2.1)
  Gent 8 (0.1) 3 (0.1)
  Clinda 4 (0.0)c 5 (0.1)
Double-drug resistant Cipro, Eryth 1854 (18.0) 870 (20.2)
  Eryth, Clinda 114 (1.1) 104 (2.4)
  Cipro, Clinda 62 (0.6) 23 (0.5)
  Cipro, Gent 8 (0.1) 12 (0.3)
  Cipro, SXT 14 (0.1) 2 (0.0)c
  Eryth, SXT 2 (0.0)c 1 (0.0)c
  Eryth, Gent 10 (0.1) 1 (0.0)c
  Gent, SXT 2 (0.0)c 0 (0.0)
Multidrug-resistant Cipro, Eryth, Clinda 4915 (47.6) 1417 (32.8)
  Cipro, Eryth, Gent 30 (0.3) 18 (0.4)
  Cipro, Eryth, SXT 23 (0.2) 7 (0.2)
  Cipro, Gent, SXT 18 (0.2) 10 (0.2)
  Eryth, Clinda, Gent 5 (0.0) 5 (0.1)
  Cipro, Clinda, Gent 6 (0.1) 3 (0.1)
  Eryth, Clinda, SXT 2 (0.0)c 1 (0.0)c
  Eryth, Gent, SXT 0 (0.0) 1 (0.0)c
  Cipro, Clinda, SXT 2 (0.0)c 0 (0.0)
  Cipro, Eryth, Lin 3 (0.0)c 0 (0.0)
  Cipro, Eryth, Clinda, Gent 858 (8.3) 214 (5.0)
  Cipro, Eryth, Clinda, SXT 58 (0.6) 14 (0.3)
  Cipro, Eryth, Gent, SXT 12 (0.1) 4 (0.1)
  Eryth, Clinda, Gent, SXT 2 (0.0)c 0 (0.0)
  Cipro, Clinda, Gent, SXT 2 (0.0)c 0 (0.0)
  Cipro, Eryth, Clinda, Gent, SXT 247 (2.4) 63 (1.5)
  Total n 10,320   4,315  
  1. aAnalysis included the following agents: gentamicin (Gent), erythromycin (Eryth), clindamycin (Clinda), trimethoprim-sulfamethoxazole (SXT), ciprofloxacin (Cipro), vancomycin (Vanc), and linezolid (Lin). Multi-drug resistance included resistance to three or more of the agents listed.
  2. bCumulative data 2002 – March 2005
  3. cn < 0.1% of total